Skip to Content
MilliporeSigma

S7071

SD-208

≥98% (HPLC), powder

Synonym(s):

2-(5-Chloro-2-fluorophenyl)pteridin-4-yl]pyridin-4-yl-amine

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

5 MG

$244.00

25 MG

$845.00

$244.00

Available to ship TODAYDetails

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C17H10ClFN6
CAS Number:
627536-09-8
Molecular Weight:
352.75
NACRES:
NA.77
PubChem Substance ID:
24899731
UNSPSC Code:
12352200
MDL number:
MFCD11519969
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

BERLXWPRSBJFHO-UHFFFAOYSA-N

SMILES string

Fc1ccc(Cl)cc1-c2nc(Nc3ccncc3)c4nccnc4n2

InChI

1S/C17H10ClFN6/c18-10-1-2-13(19)12(9-10)15-24-16-14(21-7-8-22-16)17(25-15)23-11-3-5-20-6-4-11/h1-9H,(H,20,22,23,24,25)

assay

≥98% (HPLC)

form

powder

color

off-white to tan

solubility

DMSO: >5 mg/mL

storage temp.

2-8°C

Quality Level

100

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SML2819SML1565SML0661
SD-208 ≥98% (HPLC), powder

Sigma-Aldrich

S7071

SD-208

AZ12799734 ≥98% (HPLC)

Sigma-Aldrich

SML2819

AZ12799734

A-196 ≥98% (HPLC)

Sigma-Aldrich

SML1565

A-196

ML216 ≥98% (HPLC)

Sigma-Aldrich

SML0661

ML216

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: >5 mg/mL

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 5 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear (warmed)

color

off-white to tan

color

white to beige

color

white to light brown

color

light orange to dark orange

Application

SD-208 was used to inhibit the activity of ALK5 kinase in bovine retinal vascular cells.2

Biochem/physiol Actions

SD-208 is TGF-βR I kinase inhibitor with IC50 =49 nM based on direct enzymatic assay of TGFRI kinase (ALK5) activity with a specificity of >100-fold against TGFRII and at least 17-fold over members of a panel of related protein kinases including p38a, p38b, p38d, JNK1, EGFR, MAPKAPK2, MKK6, ERK2, PKC, PKA, PKD, CDC2, and CaMKII.
SD-208 is a novel transforming growth factor beta receptor I (TGF-βR I) kinase inhibitor. SD-208 inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
SD-208 is an inhibitor of TGF β receptor 1 kinase that is reportedly effective against human malignant gliomas. It increases the lytic activity and tumor infiltration by polyclonal natural killer cells, CD8 T cells and macrophages.1

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000181242
0000181242
0000128520
0000128522
0000121143

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Martin Uhl et al.
Cancer research, 64(21), 7954-7961 (2004-11-03)
The cytokine transforming growth factor (TGF)-beta, by virtue of its immunosuppressive and promigratory properties, has become a major target for the experimental treatment of human malignant gliomas. Here we characterize the effects of a novel TGF-beta receptor (TGF-betaR) I kinase
Tanja Stüber et al.
Journal for immunotherapy of cancer, 8(1) (2020-04-19)
Immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells is effective in some hematologic tumors. In solid tumors, however, sustained antitumor responses after CAR T-cell therapy remain to be demonstrated both in the pre-clinical and clinical setting. A perceived barrier to the
Katharina Seystahl et al.
Neuro-oncology, 17(2), 254-265 (2014-08-29)
The transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF) pathways have a major role in the pathogenesis of glioblastoma, notably immunosuppression, migration, and angiogenesis, but their interactions have remained poorly understood. We characterized TGF-β pathway activity in 9
Audrey Lamora et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), 5097-5112 (2014-08-12)
Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastasis is present at diagnosis. Because transforming growth factor-β (TGFβ) has been shown to promote metastasis in many solid tumors
Rob J Van Geest et al.
Investigative ophthalmology & visual science, 51(4), 1857-1865 (2009-12-05)
Purpose. An early hallmark of preclinical diabetic retinopathy is thickening of the capillary basal lamina (BL). TGF-beta, a multipotent cytokine acting through its receptors ALK5 and -1, has been postulated to be involved in this phenomenon. In light of this
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service